(Q48949641)

17 February 2018

title

Inositol as an add-on treatment for bipolar depression. (English)

1 reference

17 February 2018

1 reference

11

Kupfer DJ

1 reference

17 February 2018

author name string

Chengappa KN

1

1 reference

17 February 2018

Levine J

2

1 reference

17 February 2018

Gershon S

3

1 reference

17 February 2018

Mallinger AG

4

1 reference

17 February 2018

Hardan A

5

1 reference

17 February 2018

Vagnucci A

6

1 reference

17 February 2018

Pollock B

7

1 reference

17 February 2018

Luther J

8

1 reference

17 February 2018

Buttenfield J

9

1 reference

17 February 2018

Verfaille S

10

1 reference

17 February 2018

publication date

1 March 2000

1 reference

17 February 2018

published in

Bipolar Disorders

1 reference

17 February 2018

volume

2

1 reference

17 February 2018

issue

1

1 reference

17 February 2018

page(s)

47-55

1 reference

17 February 2018

Neural and developmental actions of lithium: a unifying hypothesis

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Requirement of thymus-dependent lymphocytes for potentiation by adjuvants of antibody formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Inositol levels are decreased in postmortem brain of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Inositol treatment raises CSF inositol levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Double-blind, controlled trial of inositol treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Controlled trials of inositol in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Inositol treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Inositol reduces depressive-like behaviors in two different animal models of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

CSF inositol does not predict antidepressant response to inositol. Short communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

Inositol 6 g daily may be effective in depression but not in schizophrenia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

Bipolar depression: an underestimated treatment challenge

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

Inositol-induced mania?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

Bipolar depression and antidepressant-induced mania: a naturalistic study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-5618.2000.020107.X

7 January 2021

10.1034/J.1399-5618.2000.020107.X

Identifiers

DOI

1 reference

17 February 2018

1 reference

17 February 2018